葡萄糖-6-磷酸脱氢酶缺乏与卒中预后相关
该研究纳入1251例急性缺血性卒中患者,按入院时G6PD活性分为G6PD缺乏组与非缺乏组,比较3个月不良预后(mRS≥2)、mRS评分分布及死亡等结局。结果显示G6PD缺乏与3个月不良预后风险升高及院内死亡风险升高相关,提示对卒中患者进行G6PD筛查具有合理性。
要点
- 在1251例急性缺血性卒中患者中,150例(12.0%)存在G6PD缺乏。
- G6PD缺乏组3个月不良预后(mRS≥2)的校正OR为1.73(95%CI 1.08-2.76)。
- G6PD缺乏与院内死亡风险升高相关(HR 1.46,95%CI 1.37-1.84)。
核心结论
- G6PD缺乏与缺血性卒中后3个月不良预后风险升高相关,并可能增加院内死亡风险。
- 研究结果提示对卒中患者进行G6PD筛查具有合理性。
研究设计与样本
- 研究招募了1251例急性缺血性卒中患者。
- 根据入院时G6PD活性将患者分为G6PD缺乏组和非G6PD缺乏组。
- 主要终点为3个月不良预后,定义为改良Rankin量表(mRS)评分≥2(包括残疾和死亡)。
- 次要结局包括3个月时总体mRS评分、院内死亡和3个月内全因死亡。
- 采用Logistic回归和Cox模型校正潜在混杂因素后估计G6PD缺乏与结局的关联。
主要发现
- 在1251例患者中,150例(12.0%)存在G6PD缺乏。
- G6PD缺乏组大动脉粥样硬化比例更高(OR 1.53,95%CI 1.09-2.17),卒中史比例更高(OR 1.93,95%CI 1.26-2.90)。
- 两组总体mRS评分分布差异显著(校正共同OR 1.57,95%CI 1.14-2.17)。
- G6PD缺乏组3个月不良预后率更高(校正OR 1.73,95%CI 1.08-2.76;校正绝对风险增加13.0%,95%CI 2.4%-23.6%)。
- G6PD缺乏组院内死亡的风险比为1.46(95%CI 1.37-1.84)。
临床怎么用
- 对于急性缺血性卒中患者,可考虑进行G6PD筛查以识别预后不良高风险人群。
- G6PD缺乏的卒中患者可能需要更密切的监测和针对性的二级预防管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the risk of glucose-6-phosphate dehydrogenase (G6PD) on stroke prognosis, we compared outcomes between patients with stroke with and without G6PD deficiency. METHODS: The study recruited 1,251 patients with acute ischemic stroke. Patients were individually categorized into G6PD-deficiency and non-G6PD-deficiency groups according to G6PD activity upon admission. The primary endpoint was poor outcome at 3 months defined by a modified Rankin Scale (mRS) score ≥2 (including disability and death). Secondary outcomes included the overall mRS score at 3 months and in-hospital death and all death within 3 months. Logistic regression and Cox models, adjusted for potential confounders, were fitted to estimate the association of G6PD deficiency with the outcomes. RESULTS: Among 1,251 patients, 150 (12.0%) were G6PD-deficient. Patients with G6PD deficiency had higher proportions of large-artery atherosclerosis (odds ratio [OR] 1.53, 95% confidence interval [CI] 1.09-2.17) and stroke history (OR 1.93, 95% CI 1.26-2.90) compared to the non-G6PD-deficient group. The 2 groups differed significantly in the overall mRS score distribution (adjusted common OR 1.57, 95% CI 1.14-2.17). Patients with G6PD deficiency had higher rates of poor outcome at 3 months (adjusted OR 1.73, 95% CI 1.08-2.76; adjusted absolute risk increase 13.0%, 95% CI 2.4%-23.6%). The hazard ratio of in-hospital death for patients with G6PD-deficiency was 1.46 (95% CI 1.37-1.84). CONCLUSIONS: G6PD deficiency is associated with the risk of poor outcome at 3 months after ischemic stroke and may increase the risk of in-hospital death. These findings suggest the rationality of G6PD screening in patients with stroke.
引用
- Ou Z, Chen Y, Li J, et al. Glucose-6-phosphate dehydrogenase deficiency and stroke outcomes. Neurology. 2020. PMID: 32651291. doi:10.1212/WNL.0000000000010245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。